Evidence map›Paper›PMID 42060802›Full record

ReviewIndian journal of pharmacology2026

After the green light: Evaluating drugs in Phase IV studies.

Bikash Ranjan Meher, Archana Mishra

Abstract readReview
In one paragraph

Review in Indian journal of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Bikash Ranjan MeherDepartment of Pharmacology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
Archana Mishra

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractThe drug development process is lengthy and complex and Phase IV is a crucial phase within it. Phase IV studies are conducted after a drug has been approved by regulatory agencies to further evaluate its safety, efficacy, usefulness in special populations, new indications, and new formulations. There are many examples of Phase IV studies; not all Phase IV studies are postmarketing surveillance (PMS) studies, but every PMS study is an example of a Phase IV study. Phase IV studies are imperative as they evaluate the drug's effectiveness and performance in real-world clinical practice and premarketing trials have some inherent limitations. Phase IV studies can be observational or interventional studies, depending on the objectives of such studies. A drug utilization study is a Phase IV study; similarly, a registry is also an example of a Phase IV study.

Indexed as

Clinical Trials, Phase IV as TopicDrug DevelopmentHumansProduct Surveillance, PostmarketingEffectivenessgeneralizabilityPost-marketing safety surveillancereal-world study

Identifiers

PMID42060802
PMCPMC13258280

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.